Surface-enhanced Raman spectroscopy (SERS) represents a transformative leap in modern diagnostics. Specifically, SERS biomedical sensing provides molecular specificity that conventional methods often lack. By leveraging plasmonic nanomaterials and precision fabrication, researchers have developed platforms with single-molecule sensitivity. These advances enable the detection of trace biomarkers in complex biological environments. Furthermore, the evolution of nano- and microsystems since 2020 highlights a shift toward practical, on-site applications.

Various architectures now define the SERS landscape. For instance, patterned substrates and nanorods offer controlled environments for signal enhancement. Additionally, microspheres and micromotors provide dynamic sensing capabilities. These systems integrate well with microfluidic technologies to streamline sample handling. Consequently, these innovations bridge the gap between laboratory research and clinical utility.

Overcoming Challenges in SERS Biomedical Sensing

Despite significant technical progress, several hurdles remain for widespread clinical adoption. Specifically, issues like reproducibility and standardization often complicate large-scale implementation. Therefore, researchers are focusing on systematic evaluations of device architectures under real-world conditions. Moreover, integrating these sensors into compact instrumentation is essential for bedside use. Notably, recent studies emphasize the need for robust calibration to ensure consistent results across different platforms.

Looking ahead, the integration of artificial intelligence will likely enhance data interpretation. This synergy could lead to faster and more accurate diagnostics for diseases like cancer and infectious pathogens. In addition, the development of microneedles offers a potential pathway for non-invasive monitoring. Thus, the future of SERS looks promising for personalized medicine and point-of-care testing.

FAQ

What are the main advantages of SERS in a clinical setting?

SERS offers unparalleled sensitivity and high molecular specificity. It allows for the detection of biomarkers at extremely low concentrations, which is vital for early disease diagnosis and monitoring.

Why is clinical translation for SERS still limited?

Challenges such as batch-to-batch variability in nanomaterials and the lack of standardized detection protocols hinder translation. Addressing these reproducibility issues is a priority for current research to ensure diagnostic reliability.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Soufi G et al. SERS-Based Nano- and Microsystems Toward Biomedical Applications. Small. 2026 Apr 15. doi: 10.1002/smll.73304. PMID: 41983340.

Li X, et al. Surface-enhanced Raman spectroscopy for biomedical applications: recent advances and future challenges. ACS Appl Mater Interfaces. 2025;17(11):16287–379. doi: 10.1021/acsami.4c17502.

Joung Y, et al. Recent Trends in Surface-Enhanced Raman Scattering-Based In Vitro Diagnostics for Translational Biomedical Research. Annu Rev Anal Chem. 2025;18(1):335-357. doi: 10.1146/annurev-anchem-070524-093950.